Background: The plastic surgeon competes with both core and noncore physicians and surgeons for traditional cosmetic procedures. In 2007, the American Society for Aesthetic Plastic Surgery (ASAPS) and the American Society of Plastic Surgeons (ASPS) joined efforts to form a Cosmetic Medicine Task Force to further analyze this trend. Objectives: Our objective is to document and quantify the patient capture and total collections generated in a single surgeon's practice exclusive from Botulinum Toxin A and filler injections over a 10-year period. We subsequently identified the effect and importance that fillers and Botulinum Toxin A have on an active cosmetic practice. Methods: A retrospective chart review of all male and female patients who received Botulinum Toxin A or soft tissue filler injections (noninvasive aesthetic treatment) in a single surgeons practice from January 2004 to December 2013 was undertaken. Only those patients new to the practice and who were exclusively seeking out Botulinum Toxin A or fillers were included in the study. Chart review then identified which of these selected patients ultimately underwent invasive aesthetic surgery during this 10-year period. Noninvasive and invasive aesthetic surgery total collections were calculated using billing records. Results: From January 2004 to December 2013, 375 patients entered the senior surgeon's practice specifically requesting and receiving noninvasive aesthetic treatments. Of these 375 patients, 59 patients (15.7%) subsequently underwent an aesthetic surgery procedure at an average of 19 months following initial noninvasive aesthetic treatment. Of these 375 patients, 369 were female and 6 were male. The most common initial invasive aesthetic procedure performed after injectable treatment included 22 facelifts (18.5%), 21 upper eyelid blepharoplasties (17.6%), and 15 endoscopic brow lifts (12.6%). Total collections from noninvasive aesthetic sessions and invasive surgery combined represented US$762,470 over this 10-year span. This represented US$524,771 and US$396,166 in total collections for injectables and surgery respectively. Conclusions: Noninvasive aesthetic surgery is a critical part of a plastic surgery practice. A measurable and significant number of patients who sought out a single plastic surgeon exclusively for noninvasive treatment ultimately underwent traditional invasive cosmetic surgical procedures.
procedures complicates the choices for both the surgeon and the patient. 1 In 2007, a response to an increase in noninvasive aesthetic surgical procedures being offered by cosmetic medicine providers, the American Society for Aesthetic Plastic Surgery (ASAPS) and the American Society of Plastic Surgeons (ASPS) joined efforts to form a Cosmetic Medicine Task Force. 2 Their goal was to analyze this ongoing trend.
Although this was the major topic of the 2007 task force, little further objective data have been generated detailing the natural history of the patient seeking Botulinum Toxin A or fillers. Specifically, how important is that patient to an aesthetic practice? What percentage of patients seeking noninvasive aesthetic techniques ultimately undergoes invasive procedures? In order to address this question, we reviewed all patients entering a single surgeon's practice exclusively seeking Botulinum Toxin A and/or soft tissue fillers, and documented both total collections generated and the percentage of those patients who ultimately undergoes invasive aesthetic surgery in that same practice over a 10-year period.
METHODS
This study was conducted in accordance with guidelines set forth in the Declaration of Helsinki. A retrospective chart review of all male and female patients who received Botulinum Toxin A or soft tissue filler injections in a single surgeon's practice from January 2004 to December 2013 was undertaken. The senior author (J.E.Z.) practices in an academic center in the Midwest, in an area whose average household income is US$72,081. 3 Only those patients new to the practice and who were exclusively seeking out Botulinum Toxin A or fillers were included in the study. Patients requesting cosmetic evaluation who incidentally requested Botulinum Toxin A or fillers were excluded from our analysis. The 2004 time period was chosen because this coincided shortly after the FDA approval of both cosmetic Botulinum Toxin A and hyaluronic acid fillers. 2 Specifically excluded from the review were patients who had previously undergone prior aesthetic surgery of any type or any noninvasive procedure. Patients who previously underwent reconstructive or noncosmetic procedures were also excluded. Our goal was to identify those patients entering the practice for noninvasive surgery only, with no specific intention of undergoing an invasive aesthetic procedure. Chart review then identified which of these selected patients ultimately underwent invasive aesthetic surgery during this 10-year period by the senior surgeon. Data gathered included: demographics, injectable procedure specifics including type, volume and locations, type and number of cosmetic procedures performed, interval from first injection to invasive operations, number of noninvasive sessions, and total collections generated from noninvasive and invasive surgeries. Total collections from noninvasive aesthetic procedures was defined as revenue collected minus cost. This was calculated using billing records. Total collections for invasive procedures represented professional revenue only.
Study data were collected and managed using Red Cap electronic data tool hosted at the Cleveland Clinic. 4 Patient characteristics were described using medians, quartiles, means, and standard deviations for all continuous variable as well as counts and percentages for all categorical variables. A standardized t test was used to compare groups and generate P values. A chi-square test array used to compare frequency variables. All analyses were two-tailed and performed at a significance level of 0.05.
RESULTS
From January 2004 to December 2013, 375 patients entered the senior surgeon's practice specifically requesting and receiving injectable treatments of either Botulinum Toxin A or soft tissue filler with no expressed interest in invasive cosmetic surgery. Of these 375 patients, 369 were female and 6 were male. The average age of these patients was 64.2 years (range, 32-87 years). This resulted in a total of 1049 injection sessions over this same period. Of these 375 patients, 59 (16%) patients subsequently underwent at total of 99 invasive aesthetic surgery procedures at an average of 19 months following initial injection treatment. Patients underwent an average of 3 injectable sessions prior to surgery. Fillers used were hyaluronic acids, poly-L-lactic acid and calcium hydroxyapatite. Fillers were most commonly placed in the nasolabial fold and Botulinum Toxin A was most commonly used in the glabellar region. Botulinum Toxin A was the most common injectable utilized (78%) followed by hyaluronic acid fillers (64%), and 43% received both products. Of those receiving only one product type, Botulinum Toxin A or filler, conversion rates to surgery were similar (14%). A significantly higher conversion rate of 18% was seen in those patients receiving Botulinum Toxin A and fillers (P < 0.001). Conversion rates were similar when males and females were compared (16%). Of note, the senior surgeon's invasive surgical conversion rate (percentage of patients who underwent surgery following an initial consult) during this period was 75%.
Overall, 99 aesthetic surgery procedures were performed on 59 patients initially presenting for injectables alone ( Figure 1 ). The most common initial aesthetic procedure performed after injectable treatment included 22 facelifts (22.2%), 21 upper eyelid blepharoplasties (21.1%), and 15 endoscopic brow lifts (15.5%). 34 of the 59 patients who underwent surgery following an initial injectable session continued receiving further noninvasive aesthetic surgery following surgery (58%) resulting in an additional US$164,110 in incremental revenue.
In analyzing injectable volume over the 10-year period, a significant drop off in volume was seen from 2007 to 2010, followed by a significant increase from 2010 to 2013 ( Figure 2 ). The yield in the number of surgical procedures remained the same throughout the 10-year period received.
Total collections for patients who initially presented for noninvasive surgery and then went on to have surgery was US$762,470 over this 10-year span (Tables 1-4 ). This represented US$524,771 and US$396,166 in total collections for noninvasive aesthetic procedures and invasive surgery respectively. The average collections per patient who began work with noninvasive aesthetic procedures and subsequently underwent surgery was US$9603.
Total collections per year from 2008 to 2014 generated by the primary surgeon's practice that include both patients in this cohort being studied and patients who underwent noninvasive aesthetic procedures or invasive surgery is depicted in Table 5 . This averaged US$1,579,311 per year during this time period.
DISCUSSION
The face of cosmetic surgery has changed dramatically over the past 20 years. Prior to the 1990s, facial aesthetic procedures were predominantly limited to the operating room. With the advent of noninvasive cosmetic alternatives such as Botulinum toxin A, soft tissue fillers, and chemical peels, cosmetic procedures have become increasingly office based. 5 According to ASAPS, Americans spent more than US$13.5 billion on combined invasive surgical and nonsurgical procedures in 2015 alone. Of this US$13.5 billion, US$8.1 billion (68%) was spent on invasive surgical procedures, US$2.8 billion (20%) was spent on injectable procedures, and US$2.3 billion (17%) on skin rejuvenation. 1 This represented a US$1.5 billion dollar increase in expenditures for combined surgical and nonsurgical procedures from 2011 to 2016. 1 The number of noninvasive aesthetic procedures continues to increase at a far greater rate than traditional invasive procedures. Botulinum Toxin A procedures increased 6448.9% and injectables surpassed the 2 million procedure mark in 2015 for the first time. 1 In a recent publication Nahai strongly urged surgeons to adapt to the increasing popularity of injectables and pointed out that noninvasive procedures give a surgeon an important opportunity to make long-lasting connections with new patients. 6 In the same regard, Jacono further demonstrated that patients who ultimately chose to undergo a facelift surgery before the age of 50 normally had already had multiple noninvasive cosmetic procedures. 7 He showed that., noninvasive cosmetic procedures play an important role in providing the patient an alternative of care if they are not prepared for a surgical procedure. 7 Plastic surgeons have not been the sole specialty to enjoy this increase in patient volume. Competition has increased as facial plastic surgeons, oculoplastic surgeons, dermatologists, and even nontraditional surgical and nonsurgical physicians have entered the market place. Cosmetic surgery, therefore, is no longer the sole domain of the plastic surgeon. The typical aesthetic plastic surgeon performs three times the number of noninvasive cosmetic procedures compared to invasive cosmetic operations.
As reimbursement for reconstructive plastic surgery procedures has declined over the past ten years, cosmetic surgery has come to represent an increasing proportion of the plastic surgeon's revenue stream. As a result, cosmetic surgery will continue to represent an important part of plastic surgery practices, perhaps even increasing in importance over time. Core and noncore aesthetic specialties have also realized the value of these noninvasive cosmetic procedures and many have incorporated these techniques into their practice.
The plastic surgeon is, thus, presented with both opportunity and risk. These disruptive technologies represent opportunity because the number of patients seeking such procedures has expanded exponentially. The risk is the result of the significant increase in competition for these procedures.
In order to further investigate and analyze the effects of this disruptive technology, the American Society of Plastic Surgeons and the American Society of Aesthetic Plastic Surgeons formed the Joint Cosmetic medicine Task Force in 2007. 2 Through the 2007 survey involving over 1000 prospective patients and over 250 ASPS/ASAPS members the Task Force found that: (1) the public considers Botulinum Toxin A and fillers low risk procedures; (2) these prospective patients are price sensitive and are more likely to seek out less expensive physicians for these noninvasive techniques; and (3) they are as likely to go to other core and noncore physicians and surgeons as they are to go to plastic surgeons for similar services. 2 The survey further documented that these prospective patients invariably seek out plastic surgeons for invasive higher risk procedures. Of particular interest, however, was the discovery that 47% of those surveyed would consider undergoing invasive surgery by a noncore physician if they had an initial good experience with their noninvasive procedure. 2 The implication noted by the task force is clear. If prospective patients are captured early by noncore physicians when undergoing noninvasive procedures, they may be lost to the plastic surgeon when more complex operations are to be performed. Botulinum Toxin A, soft tissue fillers, and other noninvasive techniques now represent the entry way to cosmetic surgery, and this technology has the potential to "permanently change the face of the plastic surgery specialty." 2 We have addressed and expanded upon these issues by attempting to provide objective measures regarding the likelihood that these patients solely seeking noninvasive procedures will ultimately undergo invasive cosmetic operations. Stated another way, we have documented the long-term natural history of those patients exclusively seeking Botulinum Toxin A or fillers in a single cosmetic surgeons' practice.
Our results are similar to those of Dayan et al who also attempted to define the role of Botulinum Toxin A in their surgical practice. 8 In a 5-year retrospective analysis of their 225 patients who underwent facial rejuvenation, 51 (22.6%) received Botulinum Toxin A treatment prior to surgery with a mean number of 3.47 treatments. Nearly half (45.7%) of all patients undergoing facial rejuvenation surgery had Botulinum Toxin A before or after surgery. 8 Dayan et al concluded that Botulinum Toxin A services not only helped convert patients to surgery but also resulted in a continued revenue stream. 8 They did not, however, provide data regarding patients who presented requesting noninvasive procedures alone and who ultimately underwent invasive cosmetic surgery.
Our study also outlined the financial implications of offering Botulinum toxin and dermal fillers. 375 patients were introduced to the practice seeking solely either Botulinum toxin or filler or both during the 10-year span. We demonstrated a steady and significant annual revenue stream from those patients who initially sought only Botulinum Toxin A and fillers. This represented US$762,447 over 10 years or US$76,247 a year.
In order to better appreciate the relative financial contribution of Botulinum Toxin A and fillers to total practice revenue, the contribution of noninvasive procedures and traditional surgery was tabulated annually from 2008 to 2014 (Table 5 ). According to this analysis, noninvasive techniques represented an average of 14.6% of total practice collections per year. This validates the importance of providing injectables as a means of both maintaining revenue stream and potentially increasing surgical volumes.
Our study has its limitations and confounding variables. These data represent a single surgeon's experience whose practice is predominantly facial aesthetic. One might think that this may inflate the percentage of patients who converted from noninvasive to invasive surgery. In addition the fact that few marketing dollars were spent exclusive of a web site may have affected noninvasive patient volumes. Finally, the Midwestern local of the senior author's surgical practice may not equate with other areas of the country.
We were unable to determine how many patients presented for initial injectable consultations but ultimately had aesthetic surgery elsewhere. This would require extensive patient follow up that was not performed for this study. Additionally, we did not include patients who had injectable treatments elsewhere but ultimately came to the facility for their aesthetic surgical rejuvenation, of which there were several. Finally, we did not attempt to identify those patients who were initially treated with injectables by a nonplastic surgeon but ultimately came to the senior surgeon for invasive surgery. Instead we attempted to objectify only what percentage of patients presenting to a single surgeon's office exclusively for Botulinum Toxin A or soft tissue filler ultimately underwent a traditional cosmetic procedure.
CONCLUSION
The above data supply objective numbers to our joint society's contention that cosmetic injectables are a critical part of a plastic surgery practice. We have demonstrated that a measurable and significant number of patients who sought out a single plastic surgeon exclusively for nonsurgical treatment ultimately underwent traditional cosmetic surgical procedures. The financial benefits were also described.
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